Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast Cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 5, 2009, Pages 492-498

  Perez Ellis, Carole ^a   Goncalves, Anthony ^b,c   Jacquemier, Jocelyne ^b   Marty, Michel ^d   Girre, Véronique ^e   Roché, Henri ^f   Brain, Etienne ^g   Moatti, Jean Paul ^a,b   Viens, Patrice ^b,c   Le Corroller Soriano, Anne Gaëlle ^a  

^a INSERM   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e INSTITUT CURIE   (France)

^f INSTITUT CLAUDIUS REGAUD   (France)

^g CENTRE RENÉ HUGUENIN   (France)

Author keywords

Cost effectiveness analysis; Metastatic breast cancer; Trastuzumab (Herceptin)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; GENE OVEREXPRESSION; HOSPITAL COST; HUMAN; LOADING DRUG DOSE; METASTASIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; FRANCE; GENES, ERBB-2; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 70350651151     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181931277     Document Type: Article

References (31)

1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341-354.
2. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992;89:4285-4289.
3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
4. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244: 707-712.
5. Marty M, Cognetti F, Maraninchi D, et al; the M77001 study group. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment. J Clin Oncol. 2005;23:4265-4274.
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med. 2001;344:783-792.
7. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809-820.
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.
9. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353: 1673-1684.
10. Sibbald B. Making a case for a $2700-a-month drug. CMAJ. 1999;161:1173.
11. Neyt MJ, Albrecht JA, Clarysse B, et al. Cost-effectiveness of Herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital. Int J Technol Assess Health Care. 2005;21:132-137.
12. Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol. 2005;16:909-914.
13. Moatti JP, Chanut C, Benech JM. Researcher-driven versus policy-driven economic appraisal of health technologies: the case of France. Soc Sci Med. 1994;38:1625-1633.
14. Eisenberg JM. New drugs and clinical economics: analysis of cost effectiveness in the assessment of pharmaceutical innovations. Rev Infect Dis. 1984; 6(suppl 4):S905-S908.
15. Le Corroller AG, Macquart-Moulin G, Auquier P, et al. Comparative study of the costs for two hematopoietic cell specimen collections: cytapheresis and bone marrow collection [in French]. Rev Epidemiol Sante Publique. 1996; 44:133-143.
16. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
17. Peto R, Lee PN, Paige WS. Statistical analysis of the bioassay of continuous carcinogens. Br J Cancer. 1972;26:258-261.
18. Stebbing J, Copson E, O'Reilly S. Herceptin (trastuzamab) in advanced breast cancer. Cancer Treat Rev. 2000;26:287-290.
19. Dyer C. Trust's refusal to fund trastuzumab was "arbitrary." BMJ. 2006;332:747.
20. Plosker GL, Keam SJ. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs. 2006;66:449-475.
21. Garber AM. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Aff (Millwood). 2004;suppl:W4-284-296
22. Gayer T, Viscusi K. Quantifying and valuing environmental health risks. In: Mäler KG, Vincent JR, eds. The Handbook of Environmental Economics. Amsterdam, The Netherlands: Elsevier; 2005.
23. Moatti J. Ethical issues in the economic assessment of health care technologies. Health Care Anal. 1999;7:153-165.
24. Elkin EB, Weinstein MC, Winer EP, et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2004;22:854-863.
25. Kell MR, Power CP. Adjuvant trastuzumab for breast cancer: assessing HER2/neu status incurs more costs for treatment. BMJ. 2005;331:1202.
26. Bell R, Verma S, Untch M, et al. M aximizing clinical benefit with trastuzumab. Semin Oncol. 2004;31:35-44.
27. Osoba D, Burchmore M. Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin). Semin Oncol. 1999;26:84-88. (Pubitemid 29411437)
28. Spigel DR, Burstein HJ. Trastuzumab regimens for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2003;4:329-337; discussion 338-339.
29. Bala MV, Zarkin GA. On pharmacogenomics and cost-effectiveness analysis at the individual level. Pharmacoeconomics. 2005;23:527.
30. La Caze A. Does pharmacogenomics provide an ethical challenge to the utilisation of cost-effectiveness analysis by public Health Systems? Pharmacoeconomics. 2005;23:445-447.
31. Neyt M, Albrecht J, Cocquyt V. An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial. Ann Oncol. 2006;17:381-390.